Medicenna Therapeutics (TSE:MDNA) Reaches New 12-Month Low – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.75 and last traded at C$0.79, with a volume of 89049 shares changing hands. The stock had previously closed at C$0.80.

Medicenna Therapeutics Stock Performance

The stock has a market cap of C$65.89 million, a P/E ratio of -4.65 and a beta of 2.87. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88. The business has a 50 day moving average price of C$1.03 and a two-hundred day moving average price of C$1.10.

Medicenna Therapeutics (TSE:MDNA) last issued its earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%. On average, sell-side analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.